{"disease":{"id":"granuloma-annulare","name":"Granuloma annulare","therapeutic_area":"","data":{},"enrichment_level":0,"last_enriched_at":null,"visit_count":0,"created_at":"2026-04-19T18:31:21.150Z","updated_at":"2026-04-19T18:39:44.960Z","meddra_pt":null,"meddra_code":null,"icd10_codes":null,"synonyms":[],"prevalence_global":null,"prevalence_us":null,"marketed_drug_count":36,"pipeline_drug_count":0,"trial_count":0},"drugs":{"marketed":[{"drug_id":"desonide","indication_name":"Granuloma annulare","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Verdeso","generic_name":"DESONIDE","company_name":"Padagis Us","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Corticosteroid [EPC]","quality_score":10,"revenue":"2800","mechanism":""},{"drug_id":"fluticasone-propionate","indication_name":"Granuloma annulare","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cutivate","generic_name":"FLUTICASONE PROPIONATE","company_name":"Teva Pharm","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Corticosteroid","quality_score":64,"revenue":"69.0","mechanism":""},{"drug_id":"fludroxycortide","indication_name":"Granuloma annulare","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cordran","generic_name":"fludroxycortide","company_name":"Aqua Pharms","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Corticosteroid [EPC]","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"benzoyl-peroxide","indication_name":"Granuloma annulare","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Benzamycin","generic_name":"BENZOYL PEROXIDE","company_name":"Mayne Pharma","drug_phase":"marketed","molecular_target":"","drug_class":"benzoyl peroxide","quality_score":23,"revenue":null,"mechanism":""},{"drug_id":"desoximetasone","indication_name":"Granuloma annulare","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Topicort","generic_name":"DESOXIMETASONE","company_name":"Taro","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Corticosteroid [EPC]","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"fluocinolone-acetonide","indication_name":"Granuloma annulare","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Derma-Smoothe/Fs","generic_name":"FLUOCINOLONE ACETONIDE","company_name":"Eurofarma","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Corticosteroid [EPC]","quality_score":42,"revenue":null,"mechanism":""},{"drug_id":"clocortolone-pivalate","indication_name":"Granuloma annulare","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cloderm","generic_name":"CLOCORTOLONE PIVALATE","company_name":"Legacy Pharma","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Corticosteroid","quality_score":42,"revenue":null,"mechanism":""},{"drug_id":"cortisone-acetate","indication_name":"Granuloma annulare","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cortone","generic_name":"CORTISONE ACETATE","company_name":"","drug_phase":"marketed","molecular_target":"Corticosteroid-binding globulin","drug_class":"alpha-Adrenergic Agonist [EPC]","quality_score":29,"revenue":null,"mechanism":""},{"drug_id":"ulobetasol-propionate","indication_name":"Granuloma annulare","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Ultravate","generic_name":"ulobetasol propionate","company_name":"Ranbaxy","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"ulobetasol propionate","quality_score":10,"revenue":null,"mechanism":"Ultravate works by binding to the glucocorticoid receptor, triggering a cascade of anti-inflammatory effects that reduce skin inflammation."},{"drug_id":"betamethasone-dipropionate","indication_name":"Granuloma annulare","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Diprolene","generic_name":"BETAMETHASONE DIPROPIONATE","company_name":"Merck & Co.","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Corticosteroid","quality_score":51,"revenue":null,"mechanism":"Diprolene works by binding to the glucocorticoid receptor in the skin, which reduces inflammation and suppresses the immune system."},{"drug_id":"betamethasone-valerate","indication_name":"Granuloma annulare","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Betamethasone Valerate","generic_name":"BETAMETHASONE VALERATE","company_name":"Fougera Pharms Inc","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Corticosteroid","quality_score":42,"revenue":null,"mechanism":""},{"drug_id":"dexamethasone","indication_name":"Granuloma annulare","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Decadron","generic_name":"dexamethasone","company_name":"Generic (originally Merck)","drug_phase":"marketed","molecular_target":"Annexin A1, Interleukin-4, Androgen receptor","drug_class":"Corticosteroid [EPC]","quality_score":44,"revenue":null,"mechanism":""},{"drug_id":"fluticasone","indication_name":"Granuloma annulare","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Flonase","generic_name":"fluticasone propionate","company_name":"GSK (GlaxoSmithKline)","drug_phase":"marketed","molecular_target":"Cytosolic phospholipase A2, Glucocorticoid receptor, Mineralocorticoid receptor","drug_class":"Inhaled/intranasal corticosteroid","quality_score":44,"revenue":null,"mechanism":""},{"drug_id":"nasonex","indication_name":"Granuloma annulare","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Nasonex","company_name":"University of Alberta","drug_phase":"marketed","molecular_target":"Multidrug resistance protein 1, Glucocorticoid receptor, Progesterone receptor","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"methylprednisolone","indication_name":"Granuloma annulare","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Medrol","generic_name":"methylprednisolone","company_name":"Generic (originally Upjohn/Pfizer)","drug_phase":"marketed","molecular_target":"Annexin A1, Short transient receptor potential channel 5, Glucocorticoid receptor","drug_class":"Glucocorticoid (corticosteroid)","quality_score":62,"revenue":null,"mechanism":"Potent synthetic glucocorticoid with 5x hydrocortisone potency and minimal mineralocorticoid activity, used for severe inflammatory conditions."},{"drug_id":"betamethasone-benzoate","indication_name":"Granuloma annulare","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Betamethasone 17-Benzoate","generic_name":"BETAMETHASONE BENZOATE","company_name":"","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Corticosteroid","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"hydrocortisone","indication_name":"Granuloma annulare","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cortef","generic_name":"hydrocortisone","company_name":"Generic (originally Merck/Upjohn)","drug_phase":"marketed","molecular_target":"Annexin A1, Corticosteroid-binding globulin, Nitric oxide synthase, inducible","drug_class":"Corticosteroid [EPC]","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"triamcinolone","indication_name":"Granuloma annulare","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Rodinolone","generic_name":"TRIAMCINOLONE","company_name":"","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Corticosteroid","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"flixotide","indication_name":"Granuloma annulare","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Flixotide","company_name":"Mundipharma Research Limited","drug_phase":"marketed","molecular_target":"Cytosolic phospholipase A2, Glucocorticoid receptor, Mineralocorticoid receptor","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"fluticason","indication_name":"Granuloma annulare","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Fluticason","company_name":"Creighton University","drug_phase":"marketed","molecular_target":"Cytosolic phospholipase A2, Glucocorticoid receptor, Mineralocorticoid receptor","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"fluocinonide","indication_name":"Granuloma annulare","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Lidex","generic_name":"FLUOCINONIDE","company_name":"","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Corticosteroid [EPC]","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"halcinonide","indication_name":"Granuloma annulare","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Halog","generic_name":"HALCINONIDE","company_name":"Sun Pharma","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Corticosteroid [EPC]","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"ammonium-lactate","indication_name":"Granuloma annulare","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Lac-Hydrin","generic_name":"AMMONIUM LACTATE","company_name":"Sun Pharma","drug_phase":"marketed","molecular_target":"","drug_class":"alpha-Hydroxy Acid [EPC]","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"prednicarbate","indication_name":"Granuloma annulare","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Dermatop","generic_name":"PREDNICARBATE","company_name":"Bausch Health","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Corticosteroid","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"mometasone-furoate","indication_name":"Granuloma annulare","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Elocon","generic_name":"MOMETASONE FUROATE","company_name":"Merck & Co.","drug_phase":"marketed","molecular_target":"Progesterone receptor","drug_class":"Corticosteroid","quality_score":75,"revenue":null,"mechanism":"Elocon works by binding to the progesterone receptor, which reduces inflammation and immune response in the body."},{"drug_id":"diflorasone-diacetate","indication_name":"Granuloma annulare","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Psorcon","generic_name":"DIFLORASONE DIACETATE","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Corticosteroid","quality_score":39,"revenue":null,"mechanism":""},{"drug_id":"amcinonide","indication_name":"Granuloma annulare","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cyclocort","generic_name":"AMCINONIDE","company_name":"Astellas Pharma","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Corticosteroid [EPC]","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"betamethasone","indication_name":"Granuloma annulare","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Betametasone","generic_name":"BETAMETHASONE","company_name":"","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Corticosteroid","quality_score":65,"revenue":null,"mechanism":"Betamethasone works by binding to the glucocorticoid receptor, which then triggers a series of downstream effects that reduce inflammation and suppress the immune system."},{"drug_id":"cortisol","indication_name":"Granuloma annulare","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Cortisol","company_name":"University of Zurich","drug_phase":"marketed","molecular_target":"Annexin A1, Corticosteroid-binding globulin, Nitric oxide synthase, inducible","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"prednisolone","indication_name":"Granuloma annulare","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Prelone","generic_name":"prednisolone","company_name":"Generic (originally Schering)","drug_phase":"marketed","molecular_target":"Annexin A1, Corticosteroid-binding globulin, G-protein coupled bile acid receptor 1","drug_class":"Glucocorticoid (corticosteroid)","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"benoxyl","indication_name":"Granuloma annulare","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Benoxyl","company_name":"Aier School of Ophthalmology, Central South University","drug_phase":"phase_2","molecular_target":"","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"prednisolon","indication_name":"Granuloma annulare","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"prednisolon","company_name":"Hannover Medical School","drug_phase":"marketed","molecular_target":"Annexin A1, Corticosteroid-binding globulin, G-protein coupled bile acid receptor 1","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"methylprednisolon","indication_name":"Granuloma annulare","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Methylprednisolon","company_name":"Leiden University Medical Center","drug_phase":"marketed","molecular_target":"Annexin A1, Short transient receptor potential channel 5, Glucocorticoid receptor","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"flumetasone","indication_name":"Granuloma annulare","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Flucorticin","generic_name":"flumetasone","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"flumetasone","quality_score":19,"revenue":null,"mechanism":""},{"drug_id":"mometasone","indication_name":"Granuloma annulare","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"MOMETASONE","company_name":"","drug_phase":"discontinued","molecular_target":"Multidrug resistance protein 1, Glucocorticoid receptor, Progesterone receptor","drug_class":"","quality_score":null,"revenue":null,"mechanism":"12.1 Mechanism of Action Mometasone furoate nasal spray is a corticosteroid demonstrating potent anti-inflammatory properties. The precise mechanism of corticosteroid action on allergic rhinitis is not known. Corticosteroids have been shown to have a wide range of effects on multiple cell types (e.g., mast cells, eosinophils, neutrophils, macrophages, and lymphocytes) and mediators (e.g., histamine, eicosanoids, leukotrienes, and cytokines) involved in inflammation. In two clinical studies utilizing nasal antigen challenge, mometasone furoate nasal spray decreased some markers of the early- and late-phase allergic response. These observations included decreases (vs. placebo) in histamine and eosinophil cationic protein levels, and reductions (vs. baseline) in eosinophils, neutrophils, and epithelial cell adhesion proteins. The clinical significance of these findings is not known. The effect of mometasone furoate nasal spray on nasal mucosa following 12 months of treatment was examined in 46 patients with allergic rhinitis. There was no evidence of atrophy and there was a marked reduction in intraepithelial eosinophilia and inflammatory cell infiltration (e.g., eosinophils, lymphocytes, monocytes, neutrophils, and plasma cells)."},{"drug_id":"alclometasone-dipropionate","indication_name":"Granuloma annulare","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aclovate","generic_name":"ALCLOMETASONE DIPROPIONATE","company_name":"","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Corticosteroid","quality_score":10,"revenue":null,"mechanism":""}],"pipeline":[],"offLabel":[],"totalMarketed":36,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT05472636","title":"Evaluation of 41 Cases of Pediatric Granuloma Annulare","phase":"","overall_status":"COMPLETED","enrollment_count":41,"lead_sponsor_name":"Istanbul Training and Research Hospital","has_results":false},{"nct_id":"NCT03630198","title":"Pain Outcomes Following Intralesional Corticosteroid Injections","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":31,"lead_sponsor_name":"Vanderbilt University Medical Center","has_results":true},{"nct_id":"NCT07428954","title":"Using Artificial Intelligence to Help Doctors Identify Different Skin Conditions and Improve Patient Care","phase":"","overall_status":"COMPLETED","enrollment_count":16,"lead_sponsor_name":"AI Labs Group S.L","has_results":false},{"nct_id":"NCT03910543","title":"Open-label Trial of Tofacitinib in Cutaneous Sarcoidosis and Granuloma Annulare","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":15,"lead_sponsor_name":"Yale University","has_results":false},{"nct_id":"NCT05580042","title":"Study to Evaluate the Safety and Tolerability of AC-1101 Topical Gel in Patients with Granuloma Annulare","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":13,"lead_sponsor_name":"TWi Biotechnology, Inc.","has_results":false},{"nct_id":"NCT05650736","title":"Janus Kinase Inhibition in Granuloma Annulare","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":10,"lead_sponsor_name":"William Damsky","has_results":false}],"total":6},"guidelines":[],"source":"Drug Landscape verified database"}